Anti-UBE2V1

Anti-UBE2V1
Artikelnummer Größe Datenblatt Manual SDB Lieferzeit Menge Preis
NSJ-F40115-0.08ML 80 µl - -

7 - 12 Werktage*

361,00 €
NSJ-F40115-0.4ML 400 µl - -

7 - 12 Werktage*

772,00 €
 
In 1X PBS, pH 7.4, with 0.09% sodium azide. The CROC1 isoforms, also known as UBE2V1, show... mehr
Produktinformationen "Anti-UBE2V1"
In 1X PBS, pH 7.4, with 0.09% sodium azide. The CROC1 isoforms, also known as UBE2V1, show sequence similarity to ubiquitin-conjugating enzymes (UBCs, or E2s) but lack the conserved cysteine residue critical to catalytic activity of E2s.1 Northern blot analysis detected approximately 2.1- and 2.5-kb CROC1 transcripts in all human tissues examined, with the highest levels in brain, skeletal muscle, and kidney. Partial human intestinal epithelial cell cDNAs have been isolated containing the 3-primecoding sequence and 3-prime untranslated region of UBE2V1, also called UEV1.2 UEV1 does not have ubiquitin-conjugating activity in vitro. UEV1 transcripts are downregulated upon differentiation of a colon carcinoma cell line.1 Constitutive expression of exogenous UEV1 protein in these colon carcinoma cells inhibits their capacity to differentiate upon confluence and induces changes in cell cycle behavior associated with inhibition of CDK1. A heterodimeric protein complex has been identified that links TRAF6 to IKK activation.3 Peptide mass fingerprinting analysis revealed that this complex is composed of the ubiquitin conjugating enzyme UBC13 and the UBC-like protein UBE2V1, also called UEV1A. TRAF6, a RING domain protein, functions together with UBC13/UEV1A to catalyze the synthesis of unique polyubiquitin chains linked through lysine-63 (K63) of ubiquitin. Blockade of this polyubiquitin chain synthesis, but not inhibition of the proteasome, prevents the activation of IKK by TRAF6. These results unveil a new regulatory function for ubiquitin, in which IKK is activated through the assembly of K63-linked polyubiquitin chains. Protein function: Has no ubiquitin ligase activity on its own. The UBE2V1- UBE2N heterodimer catalyzes the synthesis of non-canonical poly- ubiquitin chains that are linked through Lys-63. This type of poly-ubiquitination activates IKK and does not seem to involve protein degradation by the proteasome. Plays a role in the activation of NF-kappa-B mediated by IL1B, TNF, TRAF6 and TRAF2. Mediates transcriptional activation of target genes. Plays a role in the control of progress through the cell cycle and differentiation. Plays a role in the error-free DNA repair pathway and contributes to the survival of cells after DNA damage. Promotes TRIM5 capsid-specific restriction activity and the UBE2V1-UBE2N heterodimer acts in concert with TRIM5 to generate 'Lys-63'-linked polyubiquitin chains which activate the MAP3K7/TAK1 complex which in turn results in the induction and expression of NF-kappa-B and MAPK-responsive inflammatory genes. [The UniProt Consortium]
Schlagworte: Anti-UEV-1, Anti-CROC1, Anti-CROC-1, Anti-UBE2V1, Anti-Ubiquitin-conjugating enzyme E2 variant 1, Anti-TRAF6-regulated IKK activator 1 beta Uev1A, UBE2V1 Antibody
Hersteller: NSJ Bioreagents
Hersteller-Nr: F40115

Eigenschaften

Anwendung: WB, ELISA
Antikörper-Typ: Polyclonal
Konjugat: No
Wirt: Rabbit
Spezies-Reaktivität: human, mouse
Immunogen: A portion of amino acids 113-145 from the human protein was used as the immunogen for this UBE2V1 antibody.
Format: Purified

Handhabung & Sicherheit

Lagerung: -20°C
Versand: +4°C (International: +4°C)
Achtung
Nur für Forschungszwecke und Laboruntersuchungen: Nicht für die Anwendung im oder am Menschen!
Hier kriegen Sie ein Zertifikat
oder , um Analysenzertifikate anzufordern.
Bewertungen lesen, schreiben und diskutieren... mehr
Kundenbewertungen für "Anti-UBE2V1"
Bewertung schreiben
oder , um eine Produktbewertung abzugeben.
Zuletzt angesehen